Agenus (AGEN) offered a bundle of encouraging data readouts on March 12, 2020. These included FDA Fast Track designation for the balstilimab plus zalifrelimab combination therapy, improved efficacy data for the combination, improved early indicators for AGEN1181, and a milestone payment based on GlaxoSmithKline (GSK) Shingrix royalties. Following trial data announced just a few weeks ago at the Analyst Day on February 20, Agenus saw its stock price drop as stats were slightly below the established drugs in the class, Bristol-Myers Squibb's (BMY) nivolumab (Opdivo) with ipilimumab (Yervoy). With the coronavirus market meltdown that followed,